|
Oct 9
|
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
|
|
Aug 1
|
Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
|
|
Aug 1
|
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
|
|
Jul 29
|
Top Midday Gainers
|
|
Jul 29
|
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
|
|
May 31
|
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
|
|
May 29
|
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Dec 20
|
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
|